Skip to main navigation Skip to search Skip to main content

Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway

  • Liang N. Zhang
  • , Phil Karp
  • , Christopher J. Gerard
  • , Eric Pastor
  • , Douglas Laux
  • , Keith Munson
  • , Ziying Yan
  • , Xiaoming Liu
  • , Simon Godwin
  • , Christie P. Thomas
  • , Joseph Zabner
  • , Huidong Shi
  • , Charles W. Caldwell
  • , Richard Peluso
  • , Barrie Carter
  • , John F. Engelhardt

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

38 Downloads (CityUHK Scholars)

Abstract

Pharmacologic- and gene-based therapies have historically been developed as two independent therapeutic platforms for cystic fibrosis (CF) lung disease. Inhibition of the dysregulated epithelial Na channel (ENaC) is one pharmacologic approach to enhance airway clearance in CF. We investigated pharmacologic approaches to enhance CFTR gene delivery with recombinant adeno-associated virus (rAAV) and identified compounds that significantly improved viral transduction while simultaneously inhibiting ENaC activity through an unrelated mechanism. Treatment of human CF airway epithelia with proteasome modulating agents (LLnL and doxorubicin) at the time of rAAV2 or rAAV2/5 infection dramatically enhanced CFTR gene delivery and correction of CFTR-mediated short-circuit currents. Surprisingly, these agents also facilitated long-term (15-day) functional inhibition of ENaC currents independent of CFTR vector administration. Inhibition of ENaC activity was predominantly attributed to a doxorubicin-dependent decrease in γ-ENaC subunit mRNA expression and an increase in γ-ENaC promoter methylation. This is the first report to describe the identification of compounds with dual therapeutic action that are able to enhance the efficacy of CFTR gene therapy to the airway while simultaneously ameliorating primary aspects of CF disease pathophysiology. The identification of such compounds mark a new area for drug development, not only for CF, but also for other gene therapy disease targets. Copyright © The American Society of Gene Therapy.
Original languageEnglish
Pages (from-to)990-1002
JournalMolecular Therapy
Volume10
Issue number6
DOIs
Publication statusPublished - Dec 2004
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Keywords

  • AAV
  • Adeno-associated virus
  • CFTR
  • Cystic fibrosis
  • ENaC
  • Gene therapy

Publisher's Copyright Statement

  • This full text is made available under CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/

Fingerprint

Dive into the research topics of 'Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway'. Together they form a unique fingerprint.

Cite this